संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

concordia pharmaceuticals inc. - tranylcypromine sulfate (unii: 7zat6es870) (tranylcypromine - unii:3e3v44j4z9) - tranylcypromine 10 mg - parnate is indicated for the treatment of major depressive disorder (mdd) in adult patients who have not responded adequately to other antidepressants. parnate is not indicated for the initial treatment of mdd due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see contraindications (4), warnings and precautions (5), and drug interactions (7)] . concomitant use of parnate or use in rapid succession with the products in table 1 is contraindicated. such use may cause severe or life-threatening reactions such as hypertensive crises or serotonin syndrome [see drug interactions (7.1)]. medication-free periods between administration of parnate and contraindicated agents are recommended [ see dosage and administration (2.2) and drug interactions (7.1) ]. table 1: products contraindicated with the use of parnate - other monoamine oxidase inhibitors (maois) - selective serotonin reuptake inhibitors (ssris) and serotonin and norepinephrine reuptake inh

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - tranylcypromine sulfate, quantity: 13.68 mg (equivalent: tranylcypromine, qty 10 mg) - tablet, film coated - excipient ingredients: sucrose; erythrosine; magnesium stearate; gelatin; calcium sulfate dihydrate; maize starch; carnauba wax; titanium dioxide; hypromellose; propylene glycol; iron oxide yellow; iron oxide red; iron oxide black; cochineal - indications as at 5 october 1998: treatment of major depression.

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

lime pharma ltd - tranylcypromine sulphate - coated tablets - 10 milligram - monoamine oxidase inhibitors, non-selective

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - tranylcypromine sulfate, quantity: 13.7 mg (equivalent: tranylcypromine, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; carmellose sodium; calcium sulfate dihydrate; titanium dioxide; hypromellose; propylene glycol; iron oxide yellow; iron oxide red; iron oxide black; cochineal - the treatment of major depression

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - tranylcypromine sulfate - oral tablet - 10mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

rivopharm (uk) ltd - tranylcypromine sulfate - oral tablet - 10mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - tranylcypromine sulfate - oral tablet - 10mg

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals ltd - tranylcypromine sulfate - coated tablet - 10 base milligrams - monoamine oxidase inhibitors, non-selective; tranylcypromine

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

amdipharm limited - tranylcypromine - coated tablet - 10 milligram(s) - monoamine oxidase inhibitors, non-selective; tranylcypromine

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine; tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine - film coated tablet - 10 mg - active: tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine excipient: calcium sulfate carnauba wax red spectraspray acsl0673 erythrosine gelatin hypromellose magnesium stearate maize starch propylene glycol shellac sucrose active: tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine excipient: calcium sulfate carnauba wax erythrosine gelatin magnesium stearate maize starch opadry red 06h250000 sucrose - parnate is indicated for the treatment of symptoms of depressive illness especially where treatment with other types of anti-depressants has failed. it is not recommended for use in mild depressive states resulting from temporary situational difficulties.